Details for New Drug Application (NDA): 040662
✉ Email this page to a colleague
NDA 040662 describes METHYLPREDNISOLONE SODIUM SUCCINATE, which is a drug marketed by Abraxis Pharm, Amneal, Bedford Labs, Elkins Sinn, Eugia Pharma, Fresenius Kabi Usa, Hikma, Intl Medication, Sagent Pharms Inc, Teva Parenteral, Tianjin Kingyork, and Watson Labs, and is included in thirty-three NDAs. It is available from seven suppliers. Additional details are available on the METHYLPREDNISOLONE SODIUM SUCCINATE profile page.
The generic ingredient in METHYLPREDNISOLONE SODIUM SUCCINATE is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
The generic ingredient in METHYLPREDNISOLONE SODIUM SUCCINATE is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
Summary for 040662
| Tradename: | METHYLPREDNISOLONE SODIUM SUCCINATE |
| Applicant: | Bedford Labs |
| Ingredient: | methylprednisolone sodium succinate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 40MG BASE/VIAL | ||||
| Approval Date: | Feb 21, 2007 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
